risk-stratification criteria before ordering CTPA. They also may be more visible to clinicians than peer comparisons that are communicated through an online dashboard or email. Further, targeted interventions through the electronic health record could potentially reduce alert fatigue by decreasing the overall number of reminders for physicians.
By shaping physician behavior and performance measures, clinical practice guidelines could help or hinder efforts to balance overuse and underuse. This is especially critical for chronic conditions such as diabetes or cardiovascular disease, in which management must be continuously reevaluated as patient health, treatment goals, and medical knowledge evolve. While initiatives to decrease use of unnecessary services such as Choosing Wisely largely address 1-time services (eg, antibiotics for upper respiratory tract infections), 1 most care involves ongoing testing or treatment decisions for chronic disease. Guidelines should therefore specify when to deintensify care-stopping or scaling back the intensity or frequency of routine services. 2 To better understand the balance between overuse and underuse in current guidelines, we examined whether guidelines in 2 major clinical areas with well-developed guidelines preferentially recommend intensification rather than deintensification.
Methods | We identified all current guidelines for diabetes and cardiovascular disease (n = 22) released from January 1, 2012, through April 30, 2016, by 7 major guideline developers representing federal organizations or professional societies and meeting the plurality of standards set by the National Academy of Medicine. 3 We included services provided in the ambulatory setting, to the same patient over time, and under a primary care physician's discretion. We excluded pediatric, palliative, perioperative, or prenatal services. One coder (A.A.M., W.F., or David E. Goodrich) abstracted and provisionally categorized each recommendation as intensification or deintensification (Box) using prespecified rules and tabulated across (1) guideline developers, (2) clinical services, and (3) evidence strength. At least 2 physician coders (T.P.H., T.J.C., J.B.S., E.A.K.) reviewed all recommendations for final determination of deintensification status. recommendations for intensification than deintensification of routine services. In addition, we found considerable variation in how frequently guideline developers recommend deintensification. Why do most guidelines offer so little guidance on deintensifying care? One explanation is that there is simply more evidence regarding intensification. Randomized clinical trials, the underlying source for most guidelines, focus on generating evidence for initiating or intensifying treatment. Our finding that most "strong evidence" recommendations pertain to intensification supports this. However, even among recommendations based on weak data, a majority focus on intensification.
The large variation detected across guideline developers underscores a second explanation-developers' inconsistent engagement with existing evidence on benefit and harm. This reflects the widespread predilection for generalizing benefits observed in homogenous trial populations to broader populations 4 and is exacerbated by developers' tendency to provide clear, unqualified intensification recommendations (eg, "People with diabetes and hypertension should be treated to a systolic blood pressure goal of <140 mm Hg") while obscuring deintensification recommendations with vague or cautionary statements (eg, "Glycemic goals for some older adults might reasonably be relaxed, using individual criteria, but hyperglycemia…should be avoided"). Performance measures reflect and reinforce this inattention, rarely addressing overuse and focusing instead on intensifying care to achieve a target (eg, hemoglobin A 1c <8% [to convert to proportion of total hemoglobin, multiply by 0.01]). 5, 6 Given guidelines' potential impact on clinical practice and performance measurement, appropriate attention to deintensification is critical. Although deintensification trials would be ideal, existing trials should document harm in a more reliable manner suitable for capturing adverse events and changing patient circumstances. When extrapolating treatment effects from trials to target populations, guideline developers should use weighting schemes that account for treatment heterogeneity and can be adapted to incorporate patient preferences and enable shared decision making. 4 Where clinical data are sparse, developers should demonstrate equal restraint in recommending intensification vs deintensification. And where evidence for harm is strong, developers should provide specific guidance in the form of clear recommendations, algorithms, and decision support tools on when, how, and for whom to stop or scale back care.
